Table 1. Comparison of demographic, biochemical, angiographic and intervention related parameters of two groups .
| Cilostazol + rosuvastatin group (86 patients) | Rosuvastatin group (86 patients) | p value | |
| Age (years) | 58.86 ± 10.68 | 60.06 ± 9.8 | 0.44 |
| Sex, male/female, n (%) | 67 (77.9)/19 (22.1) | 62 (72.1)/24 (27.9) | 0.37 |
| Diabetes mellitus, n (%) | 15 (17.4) | 24 (27) | 0.10 |
| Hypertension, n (%) | 52 (60.4) | 53 (61.6) | 0.87 |
| Hyperlipidemia, n (%) | 35 (40,7) | 40 (46.5) | 0.44 |
| Smoking, n (%) | 56 (65.1) | 37 (43) | 0.004 |
| Ejection fraction, (%) | 52.41 ± 9.2 | 50.72 ± 11.53 | 0.28 |
| Systolic blood pressure, (mmHg) | 125.37 ± 16.90 | 120.03 ± 21.88 | 0.07 |
| Diastolic blood pressure, (mmHg) | 76.39 ± 15.16 | 73.63 ± 12.76 | 0.20 |
| Heart rate (beats/minute) | 71.18 ± 11.47 | 70.31 ± 13.38 | 0.64 |
| Glucose (mg/dl) | 120.12 ± 53.00 | 128.39 ± 48.68 | 0.28 |
| White blood count (× 103) | 8.33 ± 2.4 | 7.97 ± 1.72 | 0.25 |
| Hemoglobin (gr/dl) | 13.21 ± 1.94 | 12.86 ± 1.79 | 0.22 |
| Thrombocyte(× 103) | 239.43 ± 59.63 | 279.74 ± 306.26 | 0.23 |
| Creatinin (mg/dl) | 0.8 ± 0.7 | 0.9 ± 0.9 | 0.45 |
| LDL (mg/dl) | 112.50 ± 36 | 107.47 ± 45.58 | 0.42 |
| HDL (mg/dl) | 39.54 ± 9.37 | 38.90 ± 8.92 | 0.64 |
| Medications | |||
| ASA, n (%) | 86 (100) | 86 (100) | 1.0 |
| Clopidogrel, n (%) | 32 (37.2) | 32 (37.2) | 1.0 |
| Beta blocker, n (%) | 77 (89.5) | 70 (81.3) | 0.13 |
| CCB, n (%) | 10 (11.6) | 7 (8.1) | 0.44 |
| ACEI, n(%) | 54 (62.7) | 59 (68.6) | 0.42 |
| ARB, n (%) | 14 (16.2) | 10 (11.6) | 0.37 |
| Statin, n (%) | 33 (38.3) | 36 (41.8) | 0.64 |
| OAD, n (%) | 8 (9.3) | 16 (18.6) | 0.07 |
| PPI, n (%) | 28 (32.5) | 27 (31.3) | 0.87 |
| Target vessel n (%) | 0.72 | ||
| LAD | 32 | 32 | |
| CX | 24 | 24 | |
| RCA | 18 | 20 | |
| LAD/CX | 8 | 4 | |
| LAD/RCA | 1 | 3 | |
| RCA/CX | 3 | 2 | |
| LAD/RCA/CX | 0 | 1 | |
| Lesion type, n (%) | 0.43 | ||
| A | 4 | 3 | |
| B1 | 42 | 36 | |
| B2 | 8 | 15 | |
| C | 32 | 32 | |
| Lesion length, mm (mean ± SD) | 30.89 ± 35.89 | 26.91 ± 14.28 | 0.34 |
| SYNTAX score | 9.62 ± 4.94 | 11.11 ± 6.57 | 0.22 |
| Procedure | 0.44 | ||
| Direct stent, n (%) | 52 (60.5) | 47 (54.7) | |
| PTCA+stent, n (%) | 34 (39.5) | 39 (45.3) | |
| Stent length, mm (mean ± SD) | 30.89 ± 35.89 | 26.91 ± 14.28 | 0.34 |
| Stent diameter, mm (mean ± SD) | 3.03 ± 0.46 | 2.8 ± 0.44 | 0.44 |
| Amount of stent used per procedure | 1.51 ± 0.77 | 1.4 ± 0.71 | 0.47 |
| Procedure time, min (mean ± SD) | 20.16 ± 7.33 | 20.56 ± 6.93 | 0.70 |
| Use of IIb/IIIa inhibitors, n (%) | 0 (0) | 0 (0) | 1.0 |
| Quantitative angiographic analysis | |||
| Pre-procedure | |||
| RLD | 3.02 ± 0.47 | 2.8 ± 0.46 | 0.13 |
| MLD | 0.32 ± 0.25 | 0.34 ± 0.24 | 0.62 |
| % stenosis | 89.23 ± 8.38 | 87.81 ± 9.17 | 0.30 |
| Post-procedure | |||
| RLD | 3.02 ± 0.47 | 2.88 ± 0.48 | 0.11 |
| MLD | 3.02 ± 0.48 | 2.87 ± 0.47 | 0.10 |
| % stenosis | 0.23 ± 2.15 | 0.46 ± 3.03 | 0.56 |
ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; ASA, asetyl salisilic acid; CCB, calcium channel blocker; CX, left circumflex artery; HDL, high density lipoprotein; LAD, left anterior descending artery; LDL, low density lipoprotein; min, minute; MLD, minimal luminal diameter; n, patient count; OAD, oral antidiabetic; PPI, proton pump inhibitor; PTCA, percutaneous transluminal coronary angioplasty; RCA, right coronary artery; RLD, reference lumen diameter; RVD, reference luminal diameter; SD, standard deviation; UFH, unfractionated heparin.